rxi-109
Nucleic acidexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01640912)
Timeline
Indications
Mechanism of action
- Connective tissue growth factorINHIBITOR
CCN2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- rxi-109
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02599064 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | RXi Pharmaceuticals |
| NCT02246465 | Phase 2 | Jul 1, 2014 | RXi Pharmaceuticals |
| NCT02079168 | Phase 2 | Mar 1, 2014 | RXi Pharmaceuticals |
| NCT02030275 | Phase 2 | Nov 1, 2013 | RXi Pharmaceuticals |
| NCT01780077 | Phase 1 | Dec 1, 2012 | RXi Pharmaceuticals |
| NCT01640912 | Phase 1 | Jun 1, 2012 | RXi Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RXi Pharmaceuticals | For profit | 6 | 6 | 2 | 2012 |
1 organizations
Page 1 / 1